行情

IOVA

IOVA

Iovance
NASDAQ

实时行情|Nasdaq Last Sale

22.52
-0.10
-0.44%
交易中 12:53 11/14 EST
开盘
22.43
昨收
22.62
最高
22.67
最低
22.07
成交量
29.00万
成交额
--
52周最高
26.59
52周最低
7.26
市值
28.42亿
市盈率(TTM)
-16.6052
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IOVA 新闻

  • 鲍威尔对经济增长表达坚定信心 称几乎没有脱轨风险
  • 新浪美股.18分钟前
  • 美联储威廉姆斯:利率处于适当水平 不会进一步降息
  • 新浪美股.20分钟前
  • 午盘:关注鲍威尔国会证词 美股继续走低
  • 新浪美股.51分钟前
  • 阿里时隔七年重回港交所 将与腾讯争“港股之王”?
  • 中国新闻网.1小时前

更多

所属板块

生物技术和医学研究
-0.19%
制药与医学研究
-0.54%

热门股票

名称
价格
涨跌幅

IOVA 简况

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
展开

Webull提供Iovance Biotherapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。